OraSure Technologies, Inc. (NASDAQ:OSUR) saw a significant drop in short interest in June. As of June 15th, there was short interest totalling 2,664,000 shares, a drop of 15.3% from the May 15th total of 3,145,600 shares. Approximately 4.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 662,800 shares, the short-interest ratio is presently 4.0 days.
In related news, SVP Jack E. Jerrett purchased 10,000 shares of the company’s stock in a transaction on Monday, May 13th. The stock was bought at an average price of $8.55 per share, with a total value of $85,500.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have acquired 21,000 shares of company stock valued at $184,360 in the last three months. 1.70% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its holdings in shares of OraSure Technologies by 1.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,918,182 shares of the medical instruments supplier’s stock valued at $34,084,000 after purchasing an additional 31,216 shares during the last quarter. American Capital Management Inc. grew its holdings in shares of OraSure Technologies by 67.2% during the first quarter. American Capital Management Inc. now owns 2,876,592 shares of the medical instruments supplier’s stock valued at $32,074,000 after purchasing an additional 1,156,560 shares during the last quarter. Penn Capital Management Co. Inc. grew its holdings in shares of OraSure Technologies by 42.0% during the fourth quarter. Penn Capital Management Co. Inc. now owns 1,009,271 shares of the medical instruments supplier’s stock valued at $12,315,000 after purchasing an additional 298,618 shares during the last quarter. D. E. Shaw & Co. Inc. grew its holdings in shares of OraSure Technologies by 11.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 858,034 shares of the medical instruments supplier’s stock valued at $10,022,000 after purchasing an additional 85,188 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of OraSure Technologies by 10.7% during the fourth quarter. Geode Capital Management LLC now owns 716,260 shares of the medical instruments supplier’s stock valued at $8,364,000 after purchasing an additional 69,347 shares during the last quarter. 91.49% of the stock is owned by institutional investors.
Shares of NASDAQ OSUR opened at $8.58 on Friday. The company’s 50 day moving average price is $8.70. OraSure Technologies has a 52-week low of $8.01 and a 52-week high of $17.50. The firm has a market capitalization of $532.40 million, a PE ratio of 24.51, a P/E/G ratio of 2.98 and a beta of 1.21. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.52 and a quick ratio of 6.56.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. OraSure Technologies had a return on equity of 7.87% and a net margin of 11.34%. The firm had revenue of $30.12 million for the quarter, compared to analysts’ expectations of $29.66 million. During the same quarter in the prior year, the firm posted $0.07 earnings per share. OraSure Technologies’s revenue for the quarter was down 28.3% compared to the same quarter last year. As a group, research analysts anticipate that OraSure Technologies will post 0.23 EPS for the current fiscal year.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Featured Article: Front-End Load
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.